

THE LANCET

ADVERTISEMENT

CORRESPONDENCE | ONLINE FIRST

The COVID-19 MS Coalition—accelerating diagnostics, prognostics, and treatment

Weston Struwe • Edward Emmott • Melanie Bailey • Michal Sharon • Andrea Sinz • Fernando J Corrales • et al. Show all authors

Published: May 27, 2020 • DOI: https://doi.org/10.1016/S0140-6736(20)31211-3

Rapid and comprehensive genetic sequencing has shed light on the origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and allowed timely implementation of PCR tests to determine the presence of viral RNA. PCR tests for SARS-CoV-2 are some way from being reliably qualitative and will never indicate how the disease might progress in an

incluidual. As COVID-19 becomes endemic, there is a concomitant need for accurate gical assays to detect antibodies to SARS-CoV-2 antigens and ultimately tests for ostic markers to target treatment options.^{1, 2} With this considerable genetic insight, and the emerging structural information, comes associated questions regarding the molecular descriptors that contribute to disease progression, especially when we consider spread across different populations. The power of mass spectrometry to generate rapid, precise, and reproducible diagnostic information that complements genomic information and accelerates our understanding of the disease, is now becoming a reality.^{3, 4}

Mass spectrometry-based analysis can answer questions broadly falling into two categories. The first concerns multi-omic profiling of the host response, correlating prognosis with disease severity. Robust biomarkers will further our understanding of disease mechanisms and the susceptibility of certain clinical groups. The most valuable of these prognostic markers will be those indicating the transition from a beneficial immune response to one that is harmful, ultimately resulting in respiratory distress. Such data will facilitate public health efforts for population screening, defining high-risk patients, tracking disease progression, and identifying sources of vulnerability that will permit treatment stratification and minimise or prevent future coronavirus pandemics.

• View related content for this article

The second category concerns the SARS-CoV-2 viral spike glycoprotein, which is not only key for host-cell attachment but is also a major target for neutralising antibodies elicited through vaccination. Although RNA sequencing is extraordinarily informative for viral mutation or adaptation via immune selective pressure, it cannot inform on a critical feature of enveloped viruses: viral spike glycosylation. The functional role of SARS-CoV-2 spike glycans, of which there are 66 per trimer,⁵ is undetermined yet, along with associated conformational dynamics that shape receptor or antibody binding, a key factor for vaccine design. Investigating spike glycosylation and plasticity with advanced mass spectrometry methods on recombinant preparations and comparing this to wild type viral proteins is crucial to this effort.

The COVID-19 MS Coalition is a collective mass spectrometry effort that will provide molecular level information on SARS-CoV-2 in the human host and reveal pathophysiological and structural information to treat and minimise COVID-19 infection. Collaboration with colleagues at pace involves sharing of optimised methods for sample collection and data generation, processing and formatting for maximal information gain. Open datasets will enable ready access to this valuable information by the computational community to help understand antigen response mechanisms, inform vaccine development, and enable antiviral drug design. As countries across the world increase widespread testing to confirm SARS-CoV-2 exposure and assess immunity, mass spectrometry has a significant role in fighting the disease. Through collaborative actions, and the collective efforts of the COVID-19 MS Coalition, a molecular level quantitative understanding of SARS-CoV-2 and its effect will benefit all.

We declare no competing interests.

References

 Amanat F • Stadlbauer D • Strohmeier S • et al.
 A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; (published online May 12.)
 DOI:10.1038/s41591-020-0913-5

View in Article Scopus (0) • Crossref • Google Scholar 2. Wölfel R • Corman VM • Guggemos W • et al.
Virological assessment of hospitalized patients with COVID-2019.
Nature. 2020; (published online April 1.)
DOI:10.1038/s41586-020-2196-x

View in Article PubMed • Crossref • Google Scholar

3. Ihling C • Tänzler D • Hagemann S • Kehlen A • Hüttelmaier S • Sinz A Mass spectrometric identification of SARS-CoV-2 proteins from gargle solution samples of COVID-19 patients.

bioRxiv. 2020; (published online April 19.) (preprint).

DOI: 10.1101/2020.04.18.047878

View in Article A

4. Messner CB • Demichev V • Wendisch D • et al.

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics.

medRxiv. 2020; (published online May 3.) (preprint).

DOI: 10.1101/2020.04.27.20081810

View in Article A

5. Watanabe Y • Allen JD • Wrapp D • McLellan JS • Crispin M **Site-specific glycan analysis of the SARS-CoV-2 spike.** *bioRxiv.* 2020; (published online May 4.) (preprint). DOI: 10.1126/science.abb9983

View in Article Google Scholar

Article Info

Publication History

Published: May 27, 2020

Identification

DOI: https://doi.org/10.1016/S0140-6736(20)31211-3


Copyright

© 2020 Elsevier Ltd. All rights reserved.

ScienceDirect

Access this article on ScienceDirect

Related Hub



COVID-19 Resource Centre

Access the latest 2019 novel coronavirus disease (COVID-19) content from across *The Lancet* journals as it is published.

THE LANCET

THE LANCET JOURNALS

The Lancet

The Lancet Child & Adolescent Health

The Lancet Diabetes & Endocrinology

CLINICAL

Y

The Lancet Clinic Commissions Series

Picture Quiz

CONNECT

About

Contact Us

Customer Service

ACCESS

The Lancet Digital Health	GLOBAL HEALTH	Information for Readers
The Lancet Gastroenterology & Hepatology	Hub	Register
	Commissions	Subscription Options
The Lancet Global Health	Series	My Account
The Lancet Haematology	Global Burden of Disease	Existing Print Subscribers
The Lancet HIV		The Lancet Updates
The Lancet Infectious Diseases		Recommend Lancet journals to
The Lancet Microbe		your librarian
The Lancet Neurology		The Lancet App
The Lancet Oncology		The Lancet Choice
The Lancet Planetary Health		
The Lancet Psychiatry		INFORMATION
The Lancet Public Health		Authors
The Lancet Regional Health		Press
The Lancet Respiratory Medicine		Advertisers
The Lancet Rheumatology		Careers
EBioMedicine		Privacy Policy
EClinicalMedicine		Terms and Conditions
		Cookies

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.

 $\mathsf{Copyright} \, {}^{\odot}_{\!\!\!\!\!}$ 2020 Elsevier Inc. except certain content provided by third parties.

Privacy Policy Terms and Conditions

